Hansa Biopharma — December 2021
-
Argenx snags first FDA approval with Vyvgart win in generalized myasthenia gravis
-
"Vyvgart, which will go on sale in January 2022, costs $225,000 per year for a typical patient in the U.S. By comparison, a year’s treatment of myasthenia gravis with Soliris (eculizumab) — until now the only specialized drug against this autoimmune disease — costs $470,000."
-
6% op på en rigtig sur møg dag, ser godt ud….men lad os nu se om ikke MSE m.fl får den banket godt ned igen inden lukketid
-
Dagens kursudvikling undrer også mig? Den burde jo egentlig falde på investorer der tager tab til modregning. (Privat beskatning) Istedetfor drøner den op med 8% på en meget nervøs dag med store index fald? Meget mystiskt
-
MBcruise, tak for referat (-:
-
Når jeg lige hurtigt gennemgår mæglerstatistik på Nordnet, nettokøber dem jeg regner for shorts-håndlangere ca. 45.000 aktier i dag. Der er godt nok langt op til de ca. 3.000.000 shortede aktier der formentlig er, når man tæller positioner under 0,2 % med.
-
Ja utroligt så enige shorts-banden var i dag om at kursen skulle bankes ned igen. Det kostede dem så også yderligere et nettosalg af 100.000 aktier.
-
Utroligt som MSE styrer kursudviklingen i Hansa…Kører kursen op og ned efter behag
-
DNB Life Science Conference:
Investor Presentation - DNB Life Science Conference - December 16, 2021 Søren Tulstrup CE:
Webcast:
https://scene.dnb.no/brandcenter/no/scene/component/default/64501
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind